Lotus Eye Hospital and Institute Limited LOTUSEYE NSEPHARMA
Company Overview
Lotus Eye Hospital and Institute Limited, a specialty eye care hospital, provides eye care and related services in India. The company offers ReLEx SMILE, a refractive lenticule extraction small incision lenticule extraction; touch free laser; lasik eye surgery; Epi-LASIK, an epithelial laser in situ keratomileusis; Intralase, a blade-free technique to create the corneal flap; Zyoptix Supracor laser technology; robotic femto laser cataract surgery; phacoemulsification; paediatric eye care and squint surgery; and micro incision cataract surgery treatments. It provides treatment services for various eye problems, such as refractive, cataract, glaucoma, retinal disease/diabetic eye care, neuro ophthalmology, binocular vision, and cornea infections, as well as various eye related courses. The company was formerly known as Lotus Eye Care Hospital Limited and changed its name to Lotus Eye Hospital and Institute Limited in April 2013. Lotus Eye Hospital and Institute Limited was founded in 1989 and is based in Coimbatore, India.
Why Investors Should Care
Carries low leverage with a debt-to-equity ratio of 0.26.
Recent Developments
- Mar 2026 Revenue of ₹53.71 Cr (+8.4% YoY); net profit ₹8.04 L.
- Trailing 12 Months Year-on-year growth — revenue +8.4%, earnings -89.1%.
- 5-Year Trend Long-term compounding — revenue CAGR 5.3%, profit CAGR -73.0%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 5.32% |
| 1 Year: | 8.38% |
Compounded Profit Growth
| 5 Years: | -72.98% |
| 1 Year: | -89.12% |
Stock Price Performance
| 1 Year: | +48.36% |
| 6 Months: | -1.41% |
| 3 Months: | -10.59% |
| 1 Month: | -6.66% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)36.17 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Earnings shrank at -73.0% CAGR over 5 years.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP ₹ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | LOTUSEYE Lotus Eye Hospital and Institute Limited NSEPHARMA | 109.43 | - | ₹227.57 Cr | 0.00% | 1.10% | 0.13% | 5.32% | -72.98% |
| 2 | SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA | 1,899.00 | 39.73 | ₹4.56 L Cr | 0.82% | 17.94% | 13.74% | 10.39% | 10.65% |
| 3 | DIVISLAB Divi's Laboratories Limited NSEPHARMA | 9,100.00 | 94.06 | ₹2.42 L Cr | 0.36% | 18.96% | 15.32% | 10.98% | 12.08% |
| 4 | TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA | 4,857.00 | 75.99 | ₹1.64 L Cr | 0.77% | 9.05% | 25.79% | 13.27% | 20.22% |
| 5 | APOLLOHOSP Apollo Hospitals Enterprise Limited NIFTY50NSEAIPHARMA | 8,650.00 | 64.10 | ₹1.24 L Cr | 0.22% | 19.20% | 20.48% | 14.85% | 33.34% |
| 6 | LENSKART LENSKART SOLUTIONS LTD NIFTY_MIDNSEPHARMA | 684.90 | 236.17 | ₹1.19 L Cr | 0.00% | 7.21% | 5.65% | 35.38% | 66.99% |
| 7 | ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA | 1,120.00 | 22.36 | ₹1.13 L Cr | 0.09% | 19.04% | 18.59% | 16.55% | 36.99% |
| 8 | CIPLA Cipla Limited NIFTY50NSEAIPHARMA | 1,385.00 | 28.85 | ₹1.12 L Cr | 0.88% | 14.86% | 11.27% | 7.23% | 11.45% |
| 9 | LAURUSLABS Laurus Labs Limited NIFTY_MIDNSEPHARMA | 1,840.00 | 111.85 | ₹99,333.61 Cr | 0.13% | 19.53% | 16.77% | 3.77% | 4.00% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in INR.
| Metric | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Revenue | 12.25 Cr | 11.51 Cr | 13.52 Cr | 13.04 Cr | 13.55 Cr | 13.61 Cr |
| Cost of Revenue | - | 6.18 Cr | 6.80 Cr | 6.90 Cr | 6.94 Cr | 6.93 Cr |
| Gross Profit | - | 5.33 Cr | 6.72 Cr | 6.14 Cr | 6.61 Cr | 6.68 Cr |
| Operating Expenses | - | 4.92 Cr | 6.06 Cr | 6.22 Cr | 6.94 Cr | 7.30 Cr |
| Operating Income | - | 41.66 L | 65.71 L | -7.36 L | -32.57 L | -62.43 L |
| EBITDA | - | 93.65 L | 1.67 Cr | 1.04 Cr | 89.27 L | 95.27 L |
| Interest Expense | - | 9.45 L | 11.76 L | 12.49 L | 28.54 L | 33.13 L |
| Pretax Income | - | 84.20 L | 72.98 L | 7.30 L | -37.51 L | -48.13 L |
| Tax Provision | - | 58.97 L | 18.50 L | -4.28 L | -11.44 L | -16.18 L |
| Net Income | - | 25.23 L | 54.48 L | 11.58 L | -26.07 L | -31.95 L |
| Diluted EPS | - | 0.12 | 0.26 | 0.06 | -0.13 | -0.15 |
Profit & Loss (Annual)
Figures in INR.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue | - | 45.98 Cr | 47.24 Cr | 49.56 Cr | 53.71 Cr |
| Cost of Revenue | - | 22.73 Cr | 23.82 Cr | 24.90 Cr | 27.57 Cr |
| Gross Profit | - | 23.26 Cr | 23.42 Cr | 24.66 Cr | 26.15 Cr |
| Operating Expenses | - | 18.54 Cr | 20.52 Cr | 24.23 Cr | 26.51 Cr |
| Operating Income | - | 4.71 Cr | 2.91 Cr | 42.65 L | -36.65 L |
| EBITDA | - | 8.73 Cr | 7.84 Cr | 4.74 Cr | 4.55 Cr |
| Interest Expense | - | 9.76 L | 9.74 L | 35.50 L | 85.92 L |
| Pretax Income | - | 5.65 Cr | 4.01 Cr | 1.38 Cr | -5.36 L |
| Tax Provision | - | 1.57 Cr | 1.10 Cr | 64.33 L | -13.40 L |
| Net Income | - | 4.08 Cr | 2.91 Cr | 73.93 L | 8.04 L |
| Diluted EPS | - | 1.96 | 1.40 | 0.36 | 0.04 |
Balance Sheet (Annual)
Figures in INR.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Total Assets | - | 63.19 Cr | 66.63 Cr | 69.57 Cr | 82.60 Cr |
| Current Assets | - | 14.71 Cr | 14.02 Cr | 11.57 Cr | 11.37 Cr |
| Cash & Equivalents | - | 3.60 Cr | 2.65 Cr | 2.01 Cr | 1.81 Cr |
| Inventory | - | 2.79 Cr | 3.21 Cr | 3.83 Cr | 3.83 Cr |
| Receivables | - | 1.17 Cr | 1.26 Cr | 1.32 Cr | 1.21 Cr |
| Total Liabilities | - | 5.61 Cr | 7.22 Cr | 9.57 Cr | 22.46 Cr |
| Current Liabilities | - | 5.19 Cr | 6.34 Cr | 7.42 Cr | 9.34 Cr |
| Long Term Debt | - | - | - | - | 10.17 Cr |
| Total Debt | - | 67.04 L | 1.11 Cr | 3.43 Cr | 15.83 Cr |
| Total Equity | - | 57.58 Cr | 59.41 Cr | 60.00 Cr | 60.14 Cr |
| Shares Outstanding | - | 2.08 Cr | 2.08 Cr | 2.08 Cr | 2.08 Cr |
Cash Flows (Annual)
Figures in INR.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | 4.39 Cr | 5.68 Cr | 2.70 Cr | 3.02 Cr |
| Investing Cash Flow | - | -2.19 Cr | -3.68 Cr | -3.99 Cr | -12.37 Cr |
| Financing Cash Flow | - | -1.71 Cr | -3.37 Cr | -1.60 Cr | 9.03 Cr |
| Capital Expenditure | - | -3.10 Cr | -5.64 Cr | -4.83 Cr | -13.04 Cr |
| Free Cash Flow | - | 1.29 Cr | 4.03 L | -2.13 Cr | -10.03 Cr |
| Net Change in Cash | - | 48.76 L | -1.37 Cr | -2.89 Cr | -32.42 L |
Ratios (Annual)
Figures in %.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Gross Margin % | - | 50.6% | 49.6% | 49.8% | 48.7% |
| Operating Margin % | - | 10.2% | 6.2% | 0.9% | -0.7% |
| Net Margin % | - | 8.9% | 6.2% | 1.5% | 0.1% |
| ROE % | - | 7.1% | 4.9% | 1.2% | 0.1% |
| ROCE % | - | 8.1% | 4.8% | 0.7% | -0.5% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for LOTUSEYE
Lotus Eye Hospital Shares Dip 1.38% to ₹115.0: Key Levels to Watch on NSE - Diamond Pattern - siam.in
<a href="https://news.google.com/rss/articles/CBMiqwFBVV95cUxPNksxSm9lMmtkSTRLam5kQllCRFBNSXF2N1JIOUNFNWxyN3pZb2d3Z09YRkl4YjJPU016MjhCWWZETXhwMXFPUVJzdnVkd2J3MFF5blZlZFJJVnRrMHJRd2V6WGhoUldCcG5BQnVwTmtIQmdQbG1rLTVwZlRkVmU4U0JqeUpRdDBjZkViel…
Lotus Eye Hospital (LOTUSEYE) Holds Slightly Lower Near Support Levels - Technical Analysis - vinanet.vn
<a href="https://news.google.com/rss/articles/CBMirgFBVV95cUxQXzgxaHN6VVRJbVVhX2Q0em85VktNRTJyY3RpY0NHbmZDZXlNODNHT3Vzd2w1TnZUdG85OFdpQW5iTzdXMW5fT2xWLUpfeVlJa1JBRzZtTjdVTElSOG9RbjF3YXFZRVhuVE95MkFYVW9xeTRZODg0a0xxVUkyeG9sZ09NLTdsV0hTY3FZc3…
Lotus Eye Hospital (LOTUSEYE) Falters 2.34%; ₹112.37 Support in Focus Amid Selling Pressure - BPI Bull Correction - vinanet.vn
<a href="https://news.google.com/rss/articles/CBMixAFBVV95cUxQXzhtWklfaXN5SXN3MDVNbF9pTVJ1SU82ZTBaQ1ZmSUpieFo4Zklpd3R2TU9UanlvSVNlcy1EYXhnRlEzRGk3Y2VLRDVLenFsLXFjTlpmSFBaMVZ6NzFWRlZfejFSSUxpYmZkVjhRaXZGRUpCNU5OZnE3ay1jdTFjNHVnMi1taEFMYW1xV2…
Lotus Eye Hospital NSE:LOTUSEYE 29th AGM September 2026 - Kalkine India
<a href="https://news.google.com/rss/articles/CBMiuAFBVV95cUxOWFYxSkgtSTA3VjRVYUhrb0VqQzVnajNuenlTa0dUZlp3SFppRm5JU004NFlpWHRjMjB5cW9sZXItVWg0WXU1SWJQYjZDY1NTc0ZJc0JkSUVmb2NSckxBNW5TZlNVaFE1QVZ0S2JoOWpBOUtQbDFTeGNJYWlXd05BWkVWUHoxdXB2OURYaW…
Lotus (LOTUSEYE.NS) Results Breakdown: Available Data Shows the Latest Reported Performance; Stock Move - siam.in
<a href="https://news.google.com/rss/articles/CBMihwJBVV95cUxPMy1LQktKTUh1OXFwanVwa2dDLWRRWmRmaWtUTXdBdzJBbmxzMGNCUlQzZW51UUI5N0NzbmxWeEFyVHl1cG9Gd0VMc2dTdWl4dHl1LXV6NmlJRENHNmNGTXh4bmVwV0RCRWlyNG00clBiTVREYjV1Zk1IMjktZENvelN2QUE5dXVKSUNYZ1…
Lotus Eye Hospital Promoter Sangeetha Sundaramoorthy Discloses Share Acquisition Under SEBI Takeover Regulations - scanx.trade
<a href="https://news.google.com/rss/articles/CBMiggJBVV95cUxPa3RvRFdYaWFjUmJGRmF6RWc0VG05NGdlZTlCbXU3NTN6dW9GT1Ewbmh0UW42RUJRZVA2RFB6dGd1NnFUS3AwbkVJWkk0eEFfbVJudk9tV01VSmZxRnFLbFlTR19fOGlMdjNCXzlqbk1BVnljLWtLOEV0eUYxVFNVaGY0VzRfTThqaElCT2…
LOTUSEYE — Frequently Asked Questions
What is the current share price of Lotus Eye Hospital and Institute Limited (LOTUSEYE)?
As of 2026-09-08 04:53 IST, Lotus Eye Hospital and Institute Limited (LOTUSEYE) trades at ₹109.43 on NSE. Its 52-week range is ₹73.76 to ₹141.38.
What is the market capitalisation of LOTUSEYE?
Lotus Eye Hospital and Institute Limited (LOTUSEYE) has a market capitalisation of ₹227.57 Cr on NSE.
What is the return on equity (ROE) of LOTUSEYE?
LOTUSEYE has a return on equity (ROE) of 0.13%. Its return on capital employed (ROCE) is 1.10%.
Is LOTUSEYE a good stock to buy?
This page provides a data-driven analysis of Lotus Eye Hospital and Institute Limited (LOTUSEYE), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.